Sobjanek Michał, Zabłotna Monika, Lesiak Aleksandra, Michajłowski Igor, Szczerkowska-Dobosz Aneta, Sokolowska-Wojdylo Małgorzata, Nowicki Roman
Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, ul. Debinki 7, 80-952, Gdańsk, Poland,
Arch Dermatol Res. 2014 Aug;306(6):539-44. doi: 10.1007/s00403-014-1471-9. Epub 2014 Jun 6.
Vascular endothelial growth factor (VEGF) is believed to play a crucial role in neoplastic angiogenesis. Although the genetic background of basal cell carcinoma (BCC) has been analyzed in some papers, the mechanism of BCC pathogenesis is not fully understood. To the best of our knowledge, VEGF gene polymorphisms have not yet been explored. The aim of the study was to asses the frequency of three polymorphisms in the VEGF gene (-1154 G/A, -460 T/C and +405 G/C) in patients of Polish origin with BCC and control group. In addition, VEGF serum levels of patients with BCC and controls were measured. The study involved 180 patients (96 women, 84 men) with BCC and a mean age of 68.9 ± 11.8, and 215 healthy age- and sex-matched volunteers. The VEGF polymorphisms at positions -1154 and +405 were analyzed using the amplification refractory mutation system polymerase chain reaction method. To assess the VEGF gene polymorphism at position -460, we used the polymerase chain reaction restriction fragment length polymorphism method. Serum levels of VEGF protein were measured using the ELISA test. The presence of the G allele (GA or GG) in the -1154 VEGF polymorphism was associated with an increased risk of BCC development (OR = 7.28, p < 0.0001). Furthermore, the carriers of the AA genotype in -1154 VEGF polymorphism showed significantly reduced risks of BCC (OR = 0.14, p < 0.0001). It was also shown that the GTC haplotype of VEGF predisposes to BCC development (OR = 1.69, p = 0.013), while the presence of the ATG haplotype significantly reduces this risk (OR = 0.17, p = 0.00001). We have found significantly increased VEGF serum levels among BCC patients, in comparison with the healthy controls (mean 596.7 ± 393.5 pg/ml; range 60.1-931.4 vs. 255.9 ± 174.6 pg/ml; range 42.2-553.0 pg/ml; p < 0.0004). The serum levels of VEGF significantly correlated with tumor size: r = 0.41, p < 0.0001. Our results testify to the importance of -1154 G/A VEGF gene polymorphisms in altering the risk of BCC among the population from northern Poland.
血管内皮生长因子(VEGF)被认为在肿瘤血管生成中起关键作用。尽管一些论文已对基底细胞癌(BCC)的遗传背景进行了分析,但BCC的发病机制尚未完全明确。据我们所知,VEGF基因多态性尚未得到研究。本研究的目的是评估波兰裔BCC患者及对照组中VEGF基因的三种多态性(-1154 G/A、-460 T/C和+405 G/C)的频率。此外,还测量了BCC患者及对照组的VEGF血清水平。该研究纳入了180例BCC患者(96名女性,84名男性),平均年龄为68.9±11.8岁,以及215名年龄和性别匹配的健康志愿者。采用扩增阻滞突变系统聚合酶链反应法分析-1154和+405位点的VEGF多态性。为评估-460位点的VEGF基因多态性,我们使用了聚合酶链反应-限制性片段长度多态性方法。采用酶联免疫吸附测定法测量VEGF蛋白的血清水平。-1154 VEGF多态性中G等位基因(GA或GG)的存在与BCC发生风险增加相关(比值比=7.28,p<0.0001)。此外,-1154 VEGF多态性中AA基因型携带者的BCC风险显著降低(比值比=0.14,p<0.0001)。研究还表明,VEGF的GTC单倍型易导致BCC发生(比值比=1.69,p=0.013),而ATG单倍型的存在则显著降低了这种风险(比值比=0.17,p=0.00001)。我们发现,与健康对照组相比,BCC患者的VEGF血清水平显著升高(平均596.7±393.5 pg/ml;范围60.1 - 931.4 vs. 255.9±174.6 pg/ml;范围42.2 - 553.0 pg/ml;p<0.0004)。VEGF血清水平与肿瘤大小显著相关:r = 0.41,p<0.0001。我们的结果证明了-1154 G/A VEGF基因多态性在改变波兰北部人群BCC风险中的重要性。